What the business is, and whether it's a good one at a fair price.
Manufactures and sells generic pharmaceutical formulations and active pharmaceutical ingredients (APIs) across US, ex-US international, India and API markets, with a recently added US branded arm. The US generics franchise is built on 245 cumulative ANDA approvals from USFDA (225 final approvals as of late July 2026), with 6 new ANDA launches in Q4 FY26 alone; FY27 growth in this segment is guided at 10-15% in INR terms. India formulations delivered 5% FY26 growth, with specialty therapies (gynaecology, gastrology, ophthalmology) and animal healthcare outperforming the base business. Ex-US international generics grew 20% in FY26, and the API business delivered modest Q4 growth from volumes against pricing headwinds. The company entered US branded through Alembic Therapeutics with the February 2026 launch of Pivya, which produced a 100-150 bps EBITDA drag and is expected to stop weighing on margins by end-FY27. Manufacturing sits at F2/F3 facilities (ophthalmic line at full capacity, other lines at 40-60% utilisation) plus a fully operational Indore API plant; FY27 capex is guided at INR300-350 crore. Other operating expenses (34.2% of revenue), materials (23.8%) and employee costs (23.6%) are the largest cost lines, with R&D spiked to 11% of revenue in Q4 from peptide development and guided to INR750-800 crore (~8-9% of revenue) for FY27.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from ALEMBIC PHARMA LTD's filed financials and exchange disclosures
ALEMBIC PHARMA LTD is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol APLLTD.
Yes. Over the trailing twelve months ALEMBIC PHARMA LTD reported a net profit of ₹690 Cr on revenue of ₹7,784 Cr.
Yes. The dividend yield is 1.36% at the current price. It paid out 32% of its profit as dividend in FY26.
No. Debt stands at 0.24× equity, and it carries net debt of ₹1,164 Cr. That is lower than 38% of its 171 Pharmaceuticals peers.
On trailing P/E, ALEMBIC PHARMA LTD ranks 68 of 169 in Pharmaceuticals — cheaper than 60% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session ALEMBIC PHARMA LTD moves 0.93% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by ALEMBIC PHARMA LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
